Please assess the completion status of the following clinical trial:

Trial Title: Negative Beta Glucan in ICU Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In the ICU for \>2 days AND~  * Systemic antibiotics on days 1-3 of ICU OR~ * Central venous catheter on days 1-3 of ICU~* AND at least 2 of:~  * Total parenteral nutrition on days 1-3 of ICU~ * Any dialysis on days 1-3 of ICU~ * Major surgery in the 7 days before admission in the ICU~ * Pancreatitis in the 7 days before admission in the ICU~ * Use of corticosteroids for at least 3 days in the 7 days before admission~ * Use of other immunosuppressive agents in the 7 days before admission in the ICU~* In addition, the patient must have at least one of the following:~  * Fever (axillary temperature \>37.5 oC)~ * Hypothermia (axillary temperature \<35 oC)~ * Hypotension~ * Unexplained acidosis~ * Unexplained elevation in C-reactive protein~Exclusion Criteria:~* Antifungal for \>3 days~* Allergy to an echinocandin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anidulafungin (Type: EXPERIMENTAL): Patients at risk will receive therapy with anidulafungin

Based on this trial design, predict the completion outcome and termination type (if applicable).